Efficacy Safety and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
This is a Phase 2 study to assess the efficacy, safety, and tolerability of V937 administered
both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab
(MK-3475) versus pembrolizumab alone in anti-programmed cell death ligand 1
(anti-PD-L1)-treatment-naive participants with advanced/metastatic melanoma. The primary
hypothesis of the study is that V937 administered either ITu or IV in combination with
pembrolizumab results in a superior objective response rate (ORR) per Response Evaluation
Criteria In Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review
(BICR), compared to pembrolizumab alone.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.